166000.0 Da (Without post-translational modifications)
Purity:
>99% by SDS-Page and HPLC analysis
Application Notes:
The product is indicated for the treatment and prophylaxis of bleedings in patients presenting hemophilia A. The treatment with the product is related with its use to control bleeding episodes or as a perioperative management. Hemophilia A is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor VIII. This disease is manifested as excessive spontaneous or trauma-driven bleeding. The coagulation factor VIII is a robust initiator of thrombin which is later required for the generation of fibrin to form a platelet plug and its gene is expressed in the X chromosome.
* VAT and and shipping costs not included. Errors and price changes excepted
